AI-Driven Drug Discovery: Transforming Molecular Design and Therapeutic Innovation - Prof. Ruben Abagyan
By: Gayatri Srinivas
Conference Manager, InnoPharm 2026
12/30/2025
Prof. Ruben Abagyan to Deliver Keynote Session (In-Person) at InnoPharm-2026.
We are delighted to welcome Prof. Ruben Abagyan, Professor at the University of California, San Diego, as a Keynote Speaker at InnoPharm-2026.
A pioneer in computational biology and cheminformatics, Prof. Abagyan has played a pivotal role in advancing structure-based drug design and virtual screening technologies. His work integrates computational modeling, artificial intelligence, and structural biology to accelerate the identification and optimization of therapeutic candidates.
Throughout his career, he has developed innovative algorithms and platforms that allow researchers to predict molecular interactions with high precision, significantly reducing the time and cost associated with early-stage drug discovery. His contributions have been widely adopted across academia and the pharmaceutical industry.
Why It Matters:
As drug development becomes increasingly complex, AI-driven approaches are essential for improving efficiency and success rates. Prof. Abagyan’s work is helping to transform the drug discovery process by enabling faster identification of viable drug candidates and more accurate prediction of their behavior.
About Prof. Abagyan:
- Professor, University of California, San Diego
- Leader in computational drug discovery and molecular modeling
- Pioneer in AI-based approaches to therapeutic design
- Developer of widely used computational tools in drug discovery